Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.

Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;33(3):807-22. doi: 10.3233/JAD-2012-110029.

PMID:
23034521
2.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
3.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
4.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21. Review.

5.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
6.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

7.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. Review.

PMID:
23489287
8.

Frailty among Alzheimer's disease patients.

Koch G, Belli L, Giudice TL, Lorenzo FD, Sancesario GM, Sorge R, Bernardini S, Martorana A.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):507-11. Review.

PMID:
23574166
9.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

10.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48. Review.

PMID:
21861669
11.

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.

Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ.

J Neural Transm (Vienna). 2004 Mar;111(3):247-72. Epub 2003 Dec 3. Review.

PMID:
14991453
12.

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H.

Lancet Neurol. 2003 Oct;2(10):605-13. Review.

PMID:
14505582
13.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):772-91. doi: 10.1016/j.jalz.2015.05.003. Review.

PMID:
26194312
14.

Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.

Zetterberg H.

Curr Opin Psychiatry. 2015 Sep;28(5):402-9. doi: 10.1097/YCO.0000000000000179. Review.

PMID:
26147615
15.

Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.

Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ.

PLoS One. 2015 Feb 24;10(2):e0116802. doi: 10.1371/journal.pone.0116802. eCollection 2015. Review.

16.

Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.

Tang W, Huang Q, Wang Y, Wang ZY, Yao YY.

J Neurol Sci. 2014 Oct 15;345(1-2):26-36. doi: 10.1016/j.jns.2014.07.015. Epub 2014 Jul 15. Review.

PMID:
25086857
17.

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease.

Rosén C, Zetterberg H.

Curr Opin Psychiatry. 2013 May;26(3):276-82. doi: 10.1097/YCO.0b013e32835f6747. Review.

PMID:
23493130
18.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39. Review.

PMID:
22917143
19.

Analytical aspects of molecular Alzheimer's disease biomarkers.

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44. Review.

PMID:
22917140
20.

[An overview of biomarkers in Alzheimer's disease].

Rong XF, Wang XL.

Yao Xue Xue Bao. 2012 May;47(5):551-7. Review. Chinese.

PMID:
22811995
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk